REGAL- Recurrent Glioblastoma Treated with Selinexor and Temozolomide: An Open-Label, Multicenter Phase 1 Study of Selinexor with Temozolomide in Patients with Recurrent Glioblastoma
REGAL- Recurrent Glioblastoma Treated with Selinexor and Temozolomide
Sponsor: Karyopharm, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR7797
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of the research study is to see if selinexor has any effects against your cancer and toevaluate the side-effects of selinexor or selinexor in combination with temozolomide (TMZ ). One specific way cancer cells continue to grow is by getting rid of certain proteins called tumor suppressor proteins that would normally cause cancer cells to die. This study drug, Selinexor, works by keeping tumor suppressing proteins within the nucleus of the cell, thus causing the cancer cells to die or stop growing.
This study is closed
Andrew Lassman, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with glioblastoma? Yes No
Have you received first line treatment of radiation and temozlomide with or without surgery? Yes No
Has your disease recurred following this initial treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator